Histoplasmosis

Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

Retrieved on: 
星期四, 五月 9, 2024
Brain, Coccidioides, Inflammation, Aspergillosis, Amphotericin B, Lecture, Lower respiratory tract infection, Safety, Skin, Antimicrobial, Conference call, Abstract, Fungal infection, Survival, Partnership, Cell, Research, Hepatocellular carcinoma, BioNTech, Patient, Gene, Society, Histoplasmosis, Lung, Malignancy, Toxicity, Manuscript, Standard of care, Infection, Annual general meeting, Platinum, LNC, Pharmaceutical industry

BEDMINSTER, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three months ending March 31, 2024 and provides a business update.

Key Points: 
  • Conference call begins at 4:30 p.m. Eastern time today
    BEDMINSTER, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three months ending March 31, 2024 and provides a business update.
  • “We are highly encouraged by results from in vivo studies demonstrating a substantial reduction in the well-recognized toxicity of IV-docetaxel.
  • Subsequent to the close of the quarter, in April the Company raised gross proceeds of $10.0 million through a registered direct offering.
  • The live webcast will be accessible on the Investors section of the company’s website and archived for 90 days.

Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

Retrieved on: 
星期一, 二月 26, 2024
Infection, Bangladesh Technical Education Board, Division, Amphotericin B, Palliative care, Recurrence, University, Doctor of Philosophy, Malignancy, Nationwide, Physician, City, Azole, Hospital, Cryptococcosis, Nephrotoxicity, Skin, Aspergillosis, Fusarium, Lung, Fungal infection, Johns Hopkins, Vanderbilt University Medical Center, LNC, Coccidioides, Patient, Coccidioidomycosis, Histoplasmosis, Brain, Pharmaceutical industry

BEDMINSTER, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, today provided an update from its ongoing Compassionate/Expanded Use Access Program (the “Program”) with MAT2203, the Company’s proprietary, LNC-delivered oral formulation of the broad-spectrum antifungal drug amphotericin B.

Key Points: 
  • Treatment with MAT2203 was well tolerated and led to favorable clinical and radiological response and we did not observe any renal toxicity.
  • 5 additional patients have shown objective improvement in clinical markers and are continuing treatment with MAT2203 as planned.
  • 2 patients transitioned to palliative care shortly after starting therapy with MAT2203 because of unanticipated progression of their malignant disease.
  • “We continue to be excited about the ongoing, consistent positive clinical impact of MAT2203, seen in these extremely ill patients,” said Theresa Matkovits, PhD, Chief Development Officer at Matinas .

Sobi to Present Data from REAL-HLH Study at the ACR Convergence 2022 Meeting

Retrieved on: 
星期四, 十月 27, 2022
Yee, Severe cutaneous adverse reactions, Infection, American College, ACR, Virus, Priority, Rash, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, Life, Hemophagocytic lymphohistiocytosis, Tachycardia, Risk, Patient, Bacteria, Food, Vaccine, Shingles, Hypokalemia, MPH, TB, Irritability, Lymphocytosis, ODD, CMV, Rheumatology, Abdominal pain, Diarrhea, Fungus, Swedish Orphan Biovitrum, Adult, GLOBE, Full, FDA, Degenerative disease, Hematopoietic stem cell transplantation, Tuberculosis, Histoplasmosis, Cough, Constipation, Hypertension, HLH, Pharmaceutical industry, Medical device, Dentistry, MD, Fever, Tachypnea, Emapalumab

Since its approval, no study has evaluated the use of Gamifant in a larger cohort of patients in the real-world clinical setting.

Key Points: 
  • Since its approval, no study has evaluated the use of Gamifant in a larger cohort of patients in the real-world clinical setting.
  • Currently, Gamifant is not approved by the FDA for the treatment of patients with secondary HLH.
  • The FDA approval is based on data from the phase 2/3 studies (NCT01818492 and NCT02069899).
  • To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088.

TNF Alpha Inhibitors Global Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
星期一, 八月 1, 2022
Health, Pharmaceutical, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Certolizumab pegol, Warfarin necrosis, Etanercept, IBD, Immune-mediated inflammatory diseases, Inflammation, Infliximab, Tuberculosis, UC, TNF, Dermatology, Food, Blastomycosis, Rheumatoid arthritis, Janssen Biotech, Crohn's disease, Ulcerative colitis, Tumor necrosis factor, Histoplasmosis, AbbVie, Disease, Inflammatory bowel disease, Rheumatology, Person, Eastman Kodak Co. v. Image Technical Services, Inc., Gastroenterology, Pfizer, Ankylosing spondylitis, Hepatitis, Candidiasis, RA, TNA, FDA, Spondyloarthropathy, Patient, Psoriasis, Adalimumab, Overalls, Growth, Infection, Neutropenia, Amgen, Prevalence, UCB, Pharmaceutical industry, Lithium, Ablynx

The "TNF Alpha Inhibitors Global Market Report 2022: By Drug, By Route, By Disease" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "TNF Alpha Inhibitors Global Market Report 2022: By Drug, By Route, By Disease" report has been added to ResearchAndMarkets.com's offering.
  • The TNF alpha inhibitors market consists of sales of tumor necrosis factor-alpha (TNF-a) inhibitors by entities that manufacture TNF alpha inhibitors.
  • The adverse side effects of TNF alpha inhibitors on patients are expected to limit the growth of the TNF alpha inhibitors market.
  • Global TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

TNF Alpha Inhibitors Global Markets Research Report 2021: Focus on Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab pegol), & Simponi (golimumab) - ResearchAndMarkets.com

Retrieved on: 
星期一, 十二月 6, 2021
Health, Pharmaceutical, Patient, Growth, Ankylosing spondylitis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Psoriasis, Crohn's disease, Rheumatology, Hepatitis, Inflammation, Overalls, Tuberculosis, Rheumatoid arthritis, Adalimumab, Neutropenia, Candidiasis, Prevalence, Dermatology, Histoplasmosis, Janssen Biotech, Etanercept, District Co-operative Central Bank, AbbVie, Pfizer, Warfarin necrosis, RA, Food, COVID-19, IBD, Infliximab, UCB, Inflammatory bowel disease, UC, Certolizumab pegol, Ulcerative colitis, Blastomycosis, Infection, Amgen, FDA, Tumor necrosis factor, TNA, Spondyloarthropathy, Gastroenterology, TNF, Immune-mediated inflammatory diseases, Pharmaceutical industry

The "TNF Alpha Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "TNF Alpha Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The TNF alpha inhibitors market consists of sales of tumor necrosis factor-alpha (TNF-?)
  • The TNF alpha inhibitors market covered in this report is segmented by drug into remicade (infliximab), enbrel (etanercept), humira (adalimumab), cimzia (certolizumab pegol), simponi (golimumab).
  • The adverse side effects of TNF alpha inhibitors on patients are expected to limit the growth of the TNF alpha inhibitors market.

Outlook on the Choroidal Neovascularization Global Market to 2026 - by Product Type, Type of Diagnosis, Treatment Type, Application and Region - ResearchAndMarkets.com

Retrieved on: 
星期四, 九月 30, 2021
Health, General Health, Retina, Adoption, OCT, Bruch, Histoplasmosis, Fluorescein angiography, Sterilization, FA, Choroid, Diagnosis, Retinal pigment epithelium, Angioid streaks, Solution, RPE, Distortion, Patient, Choroidal neovascularization, Angiography, PDT, Indocyanine green, Industry, ARMD, ICG, Growth, Prevalence, Disease, Risk, VEGF, COVID-19, Research, CNV, Blood, R, Investment, Coronavirus, Pharmaceutical industry, Potash

Its symptoms include lipid exudation, subretinal blood and fluid, and distortion, waviness and black spots in the central vision.

Key Points: 
  • Its symptoms include lipid exudation, subretinal blood and fluid, and distortion, waviness and black spots in the central vision.
  • How has the global choroidal neovascularization market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global choroidal neovascularization market?
  • What is the structure of the global choroidal neovascularization market and who are the key players?

AAAC Wildlife Removal of Texas Gulf Coast: 5 Tips for Removing Bats from Homes and Properties from Expert Richard Lisenby

Retrieved on: 
星期二, 八月 24, 2021
City, Histoplasmosis, Mont Belvieu, Texas, GLOBE, Risk, Raccoon, Human, Hazardous waste, Hunting, Road, Oil

Nobody knows this better than Richard Lisenby, proud owner of AAAC Wildlife Removal of Texas Gulf Coast.

Key Points: 
  • Nobody knows this better than Richard Lisenby, proud owner of AAAC Wildlife Removal of Texas Gulf Coast.
  • Our experts at AAAC Wildlife Removal of Texas Gulf Coast install one-way doors at all the access points identified.
  • Leave this task to a bat control expert such as AAAC Wildlife Removal of Texas Gulf Coast.
  • AAAC Wildlife Removal of Texas Gulf Coast can take away the burden of trying to remove pesky bats from your home.

OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses

Retrieved on: 
星期三, 六月 2, 2021
Medical specialties, Animal diseases, Clinical medicine, HIV/AIDS, Infectious diseases, Zoonoses, World Health Organization, Immunology, Opportunistic infection, Histoplasmosis, Shingles, Cryptococcosis

OLUMIANT was recently approved in Japan for the treatment of pneumonia associated with COVID-19 in hospitalized adult patients.

Key Points: 
  • OLUMIANT was recently approved in Japan for the treatment of pneumonia associated with COVID-19 in hospitalized adult patients.
  • SERIOUS INFECTIONS: Patients treated with Olumiant are at risk for developing serious infections that may lead to hospitalization or death.
  • Carefully consider the risks and benefits of Olumiant prior to initiating therapy in patients with chronic or recurrent infection.
  • Among opportunistic infections, tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus, and BK virus were reported with Olumiant.

Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements

Retrieved on: 
星期二, 五月 4, 2021
Animal diseases, Medical specialties, Clinical medicine, HIV/AIDS, Zoonoses, Immune system disorders, Immunology, Opportunistic infection, Histoplasmosis, Candidiasis, Esophageal candidiasis, Cryptococcosis

"We hope that our donations as well as collaborations with other organizations speed access to baricitinib and provide treatment options for these patients.

Key Points: 
  • "We hope that our donations as well as collaborations with other organizations speed access to baricitinib and provide treatment options for these patients.
  • Follow dose adjustments as recommended in the Fact Sheet for Healthcare Providers for patients with abnormal renal, hematological and hepatic laboratory values.
  • Among opportunistic infections, tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus and BK virus were reported with Olumiant.
  • However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of research, development and commercialization.

SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting

Retrieved on: 
星期三, 一月 8, 2020
Infectious diseases, Animal diseases, Medical specialties, Histoplasmosis, Zoonoses, Aspergillosis, Coccidioidomycosis, Mycosis, Blastomycosis

The FURI study protocol was recently amended to also include patients with aspergillosis, coccidioidomycosis, histoplasmosis, blastomycosis and other emerging, difficult-to-treat fungal infections.

Key Points: 
  • The FURI study protocol was recently amended to also include patients with aspergillosis, coccidioidomycosis, histoplasmosis, blastomycosis and other emerging, difficult-to-treat fungal infections.
  • One patient with an ongoing fungal infection died while on study drug due to an underlying condition.
  • "The positive results from this second interim analysis are fully consistent with the positive outcomes observed in the first interim analysis," said David Angulo, MD., Chief Medical Officer of SCYNEXIS.
  • "Patients enrolled in the FURI study typically suffer from complex underlying medical conditions, aggravated by a severe fungal infection.